Dr. Bartosz Chmielowski, MD
Claim this profileUCLA
Expert in Melanoma
Studies Skin Cancer
19 reported clinical trials
33 drugs studied
Area of expertise
1Melanoma
Global LeaderStage IV
BRAF positive
Stage III
2Skin Cancer
Stage IV
BRAF positive
Stage III
Affiliated Hospitals
Clinical Trials Bartosz Chmielowski, MD is currently running
APG-115 + Pembrolizumab
for Skin Cancer
This study aims to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of APG-115, an MDM2 inhibitor, either alone or in combination with pembrolizumab, a programmed cell death protein-1 (PD-1) inhibitor, in patients with metastatic melanomas or advanced solid tumors. Our hypothesis is that restoration of the immune response concomitant to inhibition of the MDM2 pathway (which restores p53 functions) may promote cancer cell death, leading to effective anticancer therapy.
Recruiting1 award Phase 1 & 213 criteria
IDE196 Combinations
for Solid Tumors
This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, and other solid tumors. Phase 1 (dose escalation - monotherapy) will assess safety, tolerability and pharmacokinetics of IDE196 via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study. Phase 1 (dose escalation - binimetib combination) will assess safety, tolerability and pharmacokinetics of IDE196 and binimetinib via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study. Phase 1 (dose escalation - crizotinib combination) will assess safety, tolerability and pharmacokinetics of IDE196 and crizotinib via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study. Evaluation of safety and efficacy across multiple doses may be explored in the dose optimization part of the study. Crizotinib monotherapy with crossover to combination cohort may be assessed for safety and to show the contribution of each study drug to anti-tumor activity. As of Protocol Amendment 10, Phase 1, Phase 2 dose expansion in IDE196 monotherapy, and Phase 2 dose expansion of IDE196 in combination with binimetinib have been fully enrolled. There were no patients enrolled in the crizotinib monotherapy cohorts.
Recruiting1 award Phase 1 & 29 criteria
More about Bartosz Chmielowski, MD
Clinical Trial Related3 years of experience running clinical trials · Led 19 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Bartosz Chmielowski, MD has experience with
- Nivolumab
- Pembrolizumab
- Ipilimumab
- Dacarbazine
- IDE196
- Binimetinib
Breakdown of trials Bartosz Chmielowski, MD has run
Melanoma
Skin Cancer
Solid Tumors
Cystic Tumor
Uveal Melanoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Bartosz Chmielowski, MD specialize in?
Is Bartosz Chmielowski, MD currently recruiting for clinical trials?
Are there any treatments that Bartosz Chmielowski, MD has studied deeply?
What is the best way to schedule an appointment with Bartosz Chmielowski, MD?
What is the office address of Bartosz Chmielowski, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.